Considerations in the management of patients with philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Journal of Clinical Oncology

Volumn 29, Issue 12, 2011, Pages 1512-1516

  Kantarjian, Hagop ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MONITORING; HUMAN; LONG TERM CARE; MAJOR MOLECULAR RESPONSE; NOTE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954986886     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.9176     Document Type: Note

References (29)

1. O'Brien SG, Guilhot F, Larson Ra, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003 (Pubitemid 36302244)
2. Druker B, Guilhot F, O'Brien S, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006 (Pubitemid 44903745)
3. O'Brien SG, Guilhot F, Goodman JM, et al: International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 112:76, 2008 (abstr 186)
4. Kantarjian H, Talpaz M, O'Brien S, et al: Survival benefit with imatinib mesylate versus interferon -α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108:1835-1840, 2006 (Pubitemid 44394991)
5. Cortes J, Silver R, Kantarjian H: Chronic myeloid leukemia, in Hong W, Bast R, Hait W, et al (eds): Cancer Medicine (ed 8). Shelton, CT, People's Medical Publishing House, 2010, pp 1582-1590
6. Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354; 24:2542-2551, 2006 (Pubitemid 43882350)
7. Kantarjian HM, Giles F, Gattermann N, et al: Nilotinib (formerly amn107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546, 2007 (Pubitemid 350159618)
8. Hochhaus A, Kantarjian H, Baccarani M, et al: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309, 2007 (Pubitemid 46425867)
9. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270, 2010
10. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010
11. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al: Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferonα- in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29:1634-1642, 2011
12. Kantarjian H, O'Brien S, Cortes J, et al: Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97:1033- 1041, 20030 (Pubitemid 36173155)
13. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeoid leukemia. N Engl J Med 349:1423-1432, 2003 (Pubitemid 37211057)
14. Kantarjian H, Shan J, Jones D, et al: Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 27:3659-3663, 2009
15. Press R, Love Z, Tronnes A, et al: BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 107:4250-4256, 2006 (Pubitemid 43801348)
16. Hughes TP, Deininger MW, Hochhaus A, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors-review and recommendations for "harmonizing" current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37, 2006 (Pubitemid 43990609)
17. Kantarjian H, Schiffer C, Jones D, et al: Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: Practical advice on the use and interpretation of monitoring methods. Blood 111:1774-1780, 2008 (Pubitemid 351451481)
18. Cervantes F, Lopez-Garrido P, Montero MI, et al: Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: A study of the Spanish PETHEMA group. Haematologica 95:1317, 2010
19. Quintas-Cardama A, Cortes J, O'Brien S, et al: Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 115:2912-2921, 2009
20. Hughes TP, Hochhaus A, Branford S, et al: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116:3758-3765, 2010
21. de Lavallade H, Apperley J, Khorashad J, et al: Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention to treat analysis. J Clin Oncol 26:3358-3363, 2008
22. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820, 2006 (Pubitemid 44394987)
23. Muller MC, Cross NCP, Erben P, et al: Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:1957-1963, 2009
24. Testoni N, Marzocchi G, Luatti S, et al: Chronic myeloid leukemia: A prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: A study of the GIMEMA CML WP. Blood 114:4939-4943, 2009
25. Jabbour E, Kantarjian H, Abruzzo L, et al: Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110:2991-2995, 2007 (Pubitemid 350006953)
26. Redaelli S, Piazza R, Rostagno R, et al: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27:469-471, 2009
27. Talpaz M, Cortes JE, Deininger MW, et al: Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies. J Clin Oncol 28:489s, 2010 (abstr 6511)
28. Larson R, Druker B, Guilhot F, et al: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 111:4022-4028, 2008
29. Marin D, Bazeos A, Mahon FX, et al: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381-2388, 2010